These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15899624)

  • 41. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice.
    Goel S; Beith JM
    J Clin Oncol; 2011 Mar; 29(7):e175-6. PubMed ID: 21189375
    [No Abstract]   [Full Text] [Related]  

  • 43. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trastuzumab and breast cancer.
    Palmieri C; Powles T; Vigushin D
    N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
    [No Abstract]   [Full Text] [Related]  

  • 46. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Ewer MS; Tan-Chiu E
    J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
    [No Abstract]   [Full Text] [Related]  

  • 47. Trastuzumab cardiac side effects: only time will tell.
    Levine MN
    J Clin Oncol; 2005 Nov; 23(31):7775-6. PubMed ID: 16258081
    [No Abstract]   [Full Text] [Related]  

  • 48. Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise.
    Wonders KY; Reigle BS
    Integr Cancer Ther; 2009 Mar; 8(1):17-21. PubMed ID: 19174506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography].
    Hattori K; Nishi Y; Nakamura S; Misao H; Kikuchi M; Sasaki R; Takeda K
    Rinsho Byori; 2007 Feb; 55(2):120-5. PubMed ID: 17390714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Trastuzumab-associated cardiac dysfunction].
    Okada Y; Kanbayashi C; Sato N
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):665-9. PubMed ID: 20414023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
    Chen T; Xu T; Li Y; Liang C; Chen J; Lu Y; Wu Z; Wu S
    Cancer Treat Rev; 2011 Jun; 37(4):312-20. PubMed ID: 20952131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
    Magné N; Chargari C; MacDermed D; Conforti R; Védrine L; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Dec; 76(3):186-95. PubMed ID: 20138541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiotoxicity profile of trastuzumab.
    Ewer SM; Ewer MS
    Drug Saf; 2008; 31(6):459-67. PubMed ID: 18484781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
    Ewer MS; Ewer SM
    J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
    [No Abstract]   [Full Text] [Related]  

  • 56. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.
    Tocchetti CG; Ragone G; Coppola C; Rea D; Piscopo G; Scala S; De Lorenzo C; Iaffaioli RV; Arra C; Maurea N
    Eur J Heart Fail; 2012 Feb; 14(2):130-7. PubMed ID: 22219501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer therapy-associated cardiotoxicity and signaling in the myocardium.
    Zuppinger C; Suter TM
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):141-6. PubMed ID: 20386457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
    Schneider JW; Chang AY; Garratt A
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):22-8. PubMed ID: 12138394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Difficulties in echocardiographic monitoring of trastuzumab therapy in breast cancer patients: case report and review of recommendations].
    Duchnowska R; Szmit S; Szczylik C; Opolski G
    Kardiol Pol; 2008 Aug; 66(8):895-8. PubMed ID: 18803144
    [No Abstract]   [Full Text] [Related]  

  • 60. Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.
    Montemurro F; Redana S; Valabrega G; Martinello R; Aglietta M; Palmiero R
    J Clin Oncol; 2008 Apr; 26(12):2052-3; author reply 2053-4. PubMed ID: 18421060
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.